Insulin Glargine News and Research

RSS
Roche reports results of 5 taspoglutide Phase III studies for type 2 diabetes at 70th ADA

Roche reports results of 5 taspoglutide Phase III studies for type 2 diabetes at 70th ADA

Phase 2 proof-of-concept data for Novo Nordisk's degludec presented at ADA 2010

Phase 2 proof-of-concept data for Novo Nordisk's degludec presented at ADA 2010

Lantus and Apidra injections improve glycemic control, reduce hospital complications: Study

Lantus and Apidra injections improve glycemic control, reduce hospital complications: Study

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

Roche implements risk mitigation plan in taspoglutide Phase III programme

Roche implements risk mitigation plan in taspoglutide Phase III programme

AFREZZA non-inferior to standard therapy insulin lispro in reducing HbA1c levels of Type 1 diabetics

AFREZZA non-inferior to standard therapy insulin lispro in reducing HbA1c levels of Type 1 diabetics

Health Canada approves Victoza for treatment of adults with type 2 diabetes

Health Canada approves Victoza for treatment of adults with type 2 diabetes

Additional benefits of LAIAs over long-acting human insulin not been proven

Additional benefits of LAIAs over long-acting human insulin not been proven

Roche announces results of phase III T-emerge 3 study of taspoglutide in diabetics

Roche announces results of phase III T-emerge 3 study of taspoglutide in diabetics

Common diabetes therapies may increase cancer risk, but more research needed

Common diabetes therapies may increase cancer risk, but more research needed

Future work may uncover links between insulin use and cancer risk, say researchers

Future work may uncover links between insulin use and cancer risk, say researchers

Ipsen’s 2009 performance: Azzalure, Dysport and Decapeptyl approval, Adenuric partnership, drug sales up 7.6%

Ipsen’s 2009 performance: Azzalure, Dysport and Decapeptyl approval, Adenuric partnership, drug sales up 7.6%

Ipsen reports consolidated group sales of €1,032.8M for 2009

Ipsen reports consolidated group sales of €1,032.8M for 2009

Roche discloses results of two of eight taspoglutide T-emerge phase III studies in diabetes patients

Roche discloses results of two of eight taspoglutide T-emerge phase III studies in diabetes patients

Study to determine link between insulin glargine and cancer

Study to determine link between insulin glargine and cancer

Diabetic patients exposed to insulin glargine have higher incidence of cancer, shows study

Diabetic patients exposed to insulin glargine have higher incidence of cancer, shows study

Roche announces results of phase III taspoglutide study in diabetes patients

Roche announces results of phase III taspoglutide study in diabetes patients

Roche discloses the results of first Phase III clinical study using Taspoglutide

Roche discloses the results of first Phase III clinical study using Taspoglutide

Liraglutide drug causes less nausea and hypoglycaemia compared to exenatide

Liraglutide drug causes less nausea and hypoglycaemia compared to exenatide

Novo Nordisk's Levemir not associated with increase in the incidence of cancer

Novo Nordisk's Levemir not associated with increase in the incidence of cancer